Pharmafile Logo
Pharmafocus logo
Advanced Search

Zytiga

Showing 15 posts of 37 posts found.

J&J image

J&J to pay up to $1 billion in Aragon deal

June 18, 2013
Research and Development, Sales and Marketing Aragon, J&J, JJ, Zytiga

Johnson & Johnson could pay as much as $1 billion to buy prostate cancer specialist Aragon Pharmaceuticals. The acquisition includes …

News

Prostate cancer drug Xtandi gets nod

April 26, 2013
Sales and Marketing Xtandi, Zytiga, prostate cancer

Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …

News
Zytiga image

Zytiga extended in EU

January 15, 2013
Sales and Marketing EU, J&J, JJ, Janssen, Zytiga

Janssen is celebrating the European Commission’s decision to extend the licence for its prostate cancer treatment Zytiga. The once-daily pill …

News

New J&J chief still struggling with scandals

July 18, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Risperdal, Weldon, Xarelto, Zytiga

Johnson & Johnson has just released its Q2 figures showing sales fell back in the second quarter, a 3.5% growth …

Feature

Astellas submits new prostate cancer drug to EMA

June 28, 2012
Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide

Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …

News
Tarceva image

NICE final yes for Zytiga and Tarceva

June 27, 2012
Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga

In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …

News
Zytiga image

Janssen looks to broaden Zytiga licence

June 18, 2012
Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate

Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …

News
Zytiga image

Price cut sways NICE on Zytiga

May 16, 2012
Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer

NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance.  In its final guidance, the watchdog is recommending …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News

Prostate cancer drug extends life after chemotherapy

March 29, 2012
Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer

Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …

News
Zytiga image

Charity attacks Scottish decision on Zytiga

March 14, 2012
Sales and Marketing Janssen, NICE, PAS, Prostate Cancer Charity, Zytiga

Scotland’s medicines regulator has turned down Janssen’s prostate cancer pill Zytiga, leading to a backlash from charities. The Scottish Medicines …

News
Zytiga image

Strong Zytiga study results could increase uptake

March 12, 2012
Research and Development, Sales and Marketing IDMC, Janssen, Provenge, Zytiga, prostate

Janssen’s prostate cancer pill Zytiga could be on course to target a larger number of patients following a positive late-stage …

News
Zytiga image

Cancer Drugs Fund should not be used across the UK

March 7, 2012
Sales and Marketing CDF, Janssen, NICE, Zytiga, myloma, prostate

The Prostate Cancer Charity has said that extending England’s Cancer Drugs Fund to the UK will not solve the issue …

News
Zytiga image

Zytiga approved in Wales – for now

February 21, 2012
Sales and Marketing AWMSG, CDF, Janssen, NICE, Wales, Zytiga

Janssen’s cancer treatment Zytiga has been approved in Wales, in contrast to its rejection by NICE. The All Wales Medicines …

News
Zytiga image

Zytiga cost too high, says NICE

February 2, 2012
Sales and Marketing NICE, Zytiga

NICE is not recommending Janssen’s prostate cancer pill Zytiga because of its high cost. Zytiga (abiraterone) is not recommended, in …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025